• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin.

作者信息

Schmitz Franz-Josef, Petridou Jasmina, Jagusch Harold, Astfalk Nadine, Scheuring Sibylle, Schwarz Stefan

机构信息

Institut für Medizinische Mikrobiologie und Virologie, Heinrich-Heine Universität Düsseldorf, 40225 Düsseldorf, Germany.

出版信息

J Antimicrob Chemother. 2002 Apr;49(4):611-7. doi: 10.1093/jac/49.4.611.

DOI:10.1093/jac/49.4.611
PMID:11909834
Abstract

The aim of this study was to investigate whether a Staphylococcus aureus strain that carried an inducibly expressed erm(A) gene might exhibit resistance to the non-inducers telithromycin, ABT-773, clindamycin, quinupristin, dalfopristin or the combination quinupristin-dalfopristin after incubation in the presence of inhibitory concentrations of any of these compounds. Whenever resistant mutants were obtained, these were investigated for the molecular basis of the altered resistance phenotype. Resistant mutants were not selected with dalfopristin or quinupristin-dalfopristin, but were obtained with the other four agents. Irrespective of which drug was used for selection, all mutants were cross-resistant to clindamycin, quinupristin, telithromycin and ABT-773, and exhibited structural alterations in the erm(A) translational attenuator. The structural alterations observed included deletions of 14, 83, 121, 131, 147 or 157 bp, three different tandem duplications of 23, 25 or 26 bp, two different types of point mutation, as well as the insertion of IS256. All these alterations either completely prevented the formation of mRNA secondary structures in the erm(A) regulatory region or favoured the formation of those mRNA secondary structures that allowed translation of the erm(A) transcripts. Deletions, which were observed in almost two-thirds of the mutants, might be explained by illegitimate recombination between different parts of the erm(A) regulatory region.

摘要

相似文献

1
Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin.
J Antimicrob Chemother. 2002 Apr;49(4):611-7. doi: 10.1093/jac/49.4.611.
2
Molecular analysis of constitutively expressed erm(C) genes selected in vitro by incubation in the presence of the noninducers quinupristin, telithromycin, or ABT-773.通过在无诱导剂的奎奴普丁、泰利霉素或ABT - 773存在下孵育,对体外选择的组成型表达erm(C)基因进行分子分析。
Microb Drug Resist. 2002 Fall;8(3):171-7. doi: 10.1089/107662902760326878.
3
In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.泰利霉素和奎奴普丁/达福普汀对具有明确耐药基因型的耐甲氧西林凝固酶阴性葡萄球菌的体外活性。
Folia Microbiol (Praha). 2007;52(6):593-9. doi: 10.1007/BF02932188.
4
In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.新型酮内酯ABT-773对多重耐药革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 2001 Dec;45(12):3640-3. doi: 10.1128/AAC.45.12.3640-3643.2001.
5
In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.奎奴普丁/达福普汀、利奈唑胺、泰利霉素及对照抗菌药物对13种凝固酶阴性葡萄球菌的体外活性
J Antimicrob Chemother. 2002 Dec;50(6):933-8. doi: 10.1093/jac/dkf241.
6
Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type.根据erm基因类型,奎奴普丁-达福普汀对具有MLS(B)耐药表型的金黄色葡萄球菌菌株的杀菌活性。
Int J Antimicrob Agents. 2004 Nov;24(5):444-9. doi: 10.1016/j.ijantimicag.2004.06.016.
7
Differences in potential for selection of clindamycin-resistant mutants between inducible erm(A) and erm(C) Staphylococcus aureus genes.诱导型erm(A)和erm(C)金黄色葡萄球菌基因之间克林霉素耐药突变体选择潜力的差异。
J Clin Microbiol. 2008 Feb;46(2):546-50. doi: 10.1128/JCM.01925-07. Epub 2007 Dec 12.
8
In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.泰利霉素对具有明确大环内酯类耐药机制的西班牙肺炎链球菌分离株的体外活性。
Antimicrob Agents Chemother. 2001 Sep;45(9):2427-31. doi: 10.1128/AAC.45.9.2427-2431.2001.
9
In vitro selection of resistance to clindamycin related to alterations in the attenuator of the erm(TR) gene of Streptococcus pyogenes UCN1 inducibly resistant to erythromycin.化脓性链球菌UCN1对红霉素诱导耐药,体外筛选与erm(TR)基因弱化子改变相关的克林霉素耐药性。
J Antimicrob Chemother. 2001 Sep;48(3):411-6. doi: 10.1093/jac/48.3.411.
10
Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.ABT-773与泰利霉素对大环内酯类敏感及耐药链球菌和葡萄球菌的体外活性比较。
Antimicrob Agents Chemother. 2002 Mar;46(3):783-6. doi: 10.1128/AAC.46.3.783-786.2002.

引用本文的文献

1
Molecular basis and evolutionary cost of a novel macrolides/lincosamides resistance phenotype in .某新型大环内酯类/林可酰胺类耐药表型的分子基础及进化代价
Microbiol Spectr. 2023 Sep 19;11(5):e0044123. doi: 10.1128/spectrum.00441-23.
2
Mechanisms of Resistance to Macrolide Antibiotics among .……中对大环内酯类抗生素的耐药机制
Antibiotics (Basel). 2021 Nov 17;10(11):1406. doi: 10.3390/antibiotics10111406.
3
ResFinder 4.0 for predictions of phenotypes from genotypes.ResFinder 4.0 用于基因型到表型的预测。
J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500. doi: 10.1093/jac/dkaa345.
4
Staphylococcus aureus with an erm-mediated constitutive macrolide-lincosamide-streptogramin B resistance phenotype has reduced susceptibility to the new ketolide, solithromycin.具有 erm 介导的组成型大环内酯-林可酰胺-链阳性菌素 B 耐药表型的金黄色葡萄球菌对新型酮内酯类药物索利霉素的敏感性降低。
BMC Infect Dis. 2019 Feb 19;19(1):175. doi: 10.1186/s12879-019-3779-8.
5
Mechanisms of Bacterial Resistance to Antimicrobial Agents.细菌对抗菌药物耐药性的机制。
Microbiol Spectr. 2018 Jan;6(1). doi: 10.1128/microbiolspec.ARBA-0019-2017.
6
Lincosamides, Streptogramins, Phenicols, and Pleuromutilins: Mode of Action and Mechanisms of Resistance.林可酰胺类、链阳菌素类、氯霉素类和截短侧耳素类:作用方式及耐药机制
Cold Spring Harb Perspect Med. 2016 Nov 1;6(11):a027037. doi: 10.1101/cshperspect.a027037.
7
Modes and modulations of antibiotic resistance gene expression.抗生素抗性基因表达的模式与调控
Clin Microbiol Rev. 2007 Jan;20(1):79-114. doi: 10.1128/CMR.00015-06.
8
In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides.含新型2-氟萘啶的酮内酯类化合物的体外活性
Antimicrob Agents Chemother. 2005 Jan;49(1):309-15. doi: 10.1128/AAC.49.1.309-315.2005.
9
Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.对大环内酯类、林可酰胺类、链阳菌素类、酮内酯类和恶唑烷酮类抗生素的耐药性。
Mol Biotechnol. 2004 Sep;28(1):47-62. doi: 10.1385/MB:28:1:47.